In an important research study, patients enrolled at the Leeds Adult CF Unit to examine whether reducing the dosage of Kaftrio (Trikafta) would reduce undesirable side effects, while maintaining therapeutic benefits.
Here are the results as reported by Cystic Fibrosis News Today:
“In clinical trials, Trikafta — a combination of elexacaftor, tezacaftor, and ivacaftor sold by Vertex Pharmaceuticals — significantly lowered pulmonary exacerbations (acute worsening of symptoms) and improved lung function and quality of life with minimal side effects in people with the F508del mutation.”
“However, some patients experience insomnia, anxiety, mental fog (confusion and lack of mental clarity), and depression in real-life settings.”
“A total of 13 participants (10 females) with a median age of 35 agreed to reduce Trikafta dosage. After reducing Trikafta’s dose, mental health symptoms were resolved or eased in 10 participants.”
“Given the health benefits of Trikafta treatment in CF, every effort should be made to continue treatment while resolving or minimising any side effects”